However, recently Martin‐Broto et al reported activity in other STS subtypes and observed an above median progression‐free survival (PFS) in a single UPS case treated with palbociclib as part of a phase II trial which recruited patients overexpressing CDK4 and without overexpression of CDKN2A [36]. This evidence concerns the gene CDKN2A and telomere syndrome.